{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:04:45Z","timestamp":1771851885891,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ejpn-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ejpn.2016.04.008","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T11:43:59Z","timestamp":1462016639000},"page":"532-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Safety profile of incobotulinum toxin A [Xeomin\u00ae] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-1050","authenticated-orcid":false,"given":"Elena","family":"Carraro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Trevisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Martinuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2016.04.008_bib1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.clindermatol.2003.11.006","article-title":"Pharmacology and immunology of botulinum toxin type A","volume":"21","author":"Aoki","year":"2003","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.pmrj.2010.02.006","article-title":"Safety considerations in the use of botulinum toxins in children with cerebral palsy","volume":"2","author":"Apkon","year":"2010","journal-title":"PM R"},{"issue":"9","key":"10.1016\/j.ejpn.2016.04.008_bib3","first-page":"1006","article-title":"Use of botulinum toxin A in management of children with cerebral palsy","volume":"57","author":"Friedman","year":"2011","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.ejpn.2016.04.008_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01241398-199307000-00013","article-title":"Management of cerebral palsy with botulinum-A toxin: preliminary investigation","volume":"13","author":"Koman","year":"1993","journal-title":"J Pediatr Orthop"},{"issue":"5","key":"10.1016\/j.ejpn.2016.04.008_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","article-title":"Botulinum neurotoxin type A free of complexing proteins (XEOMIN\u00ae) in focal dystonia","volume":"67","author":"Jost","year":"2007","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ejpn.2016.04.008_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/dmcn.12246","article-title":"A systematic review of interventions for children with cerebral palsy: state of the evidence","volume":"55","author":"Novak","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejpn.2009.09.005","article-title":"The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy","volume":"14","author":"Heinen","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","article-title":"Safety and efficacy of botulinum toxin type A following long-term use","volume":"13","author":"Naumann","year":"2006","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.ejpn.2016.04.008_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1469-8749.2010.03814.x","article-title":"Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy","volume":"53","author":"O'Flaherty","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib10","unstructured":"US Food and Drug Administration, FDA's MedWatch safety alerts. http:\/\/www.fda.gov\/ForConsumers\/Consumer_Updates\/ucm164442.htm."},{"issue":"2","key":"10.1016\/j.ejpn.2016.04.008_bib11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1469-8749.2010.03870.x","article-title":"Botulinum toxin: does the black box warning justify change in practice?","volume":"53","author":"Narayanan","year":"2011","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"10.1016\/j.ejpn.2016.04.008_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejpn.2012.01.008","article-title":"Botulinum neurotoxin treatment in children with cerebral palsy: a population-based study in Norway","volume":"16","author":"Elkamil","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib13","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s00381-011-1609-4","article-title":"Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy","volume":"27","author":"Santamato","year":"2011","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.ejpn.2016.04.008_bib14","first-page":"320","article-title":"Neurorrehabilitaci\u00f3n visual de pacientes con da\u00f1o cerebral usando toxina botul\u00ednica","volume":"80","author":"Moguel-Ancheita","year":"2012","journal-title":"Cir Cir"},{"key":"10.1016\/j.ejpn.2016.04.008_bib15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2016.04.008_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0269215508099860","article-title":"Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials","volume":"23","author":"Albavera-Hern\u00e1ndez","year":"2009","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.ejpn.2016.04.008_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0404.2010.01354.x","article-title":"Efficacy and safety of NT 201 for upper limb spasticity of various etiologies \u2013 a randomized parallel-group study","volume":"122","author":"Barnes","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ejpn.2016.04.008_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0269215511421355","article-title":"An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial","volume":"26","author":"Hesse","year":"2012","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.ejpn.2016.04.008_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","article-title":"Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX+) in healthy volunteers","volume":"112","author":"Jost","year":"2005","journal-title":"J Neural Transm"},{"issue":"5","key":"10.1016\/j.ejpn.2016.04.008_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Kanovsk\u00fd","year":"2009","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.ejpn.2016.04.008_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Ka\u0148ovsk\u00fd","year":"2011","journal-title":"J Rehabil Med"},{"issue":"3","key":"10.1016\/j.ejpn.2016.04.008_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00702-012-0892-x","article-title":"Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke","volume":"120","author":"Santamato","year":"2013","journal-title":"J Neural Transm"},{"issue":"4","key":"10.1016\/j.ejpn.2016.04.008_bib23","first-page":"483","article-title":"Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study","volume":"49","author":"Santamato","year":"2013","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.ejpn.2016.04.008_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpn.2006.08.006","article-title":"European consensus table 2006 on botulinum toxin for children with cerebral palsy","volume":"10","author":"Heinen","year":"2006","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1468-1331.2003.00619.x","article-title":"Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres","volume":"10","author":"Bakheit","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ejpn.2016.04.008_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Non-inferiority trials: design concepts and issues \u2013 the encounters of academic consultants in statistics","volume":"22","author":"D'Agostino","year":"2003","journal-title":"Stat Med"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379816300125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379816300125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T13:21:58Z","timestamp":1536758518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379816300125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1090379816300125"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2016.04.008","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profile of incobotulinum toxin A [Xeomin\u00ae] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2016.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}